These results support further investigation into EPI-X4 derivatives with increased stability [39,51] as adjuncts to CD19-targeted therapies, offering a promising strategy for enhancing clinical outcomes in CXCR4-dependent lymphomas. The gene discussed is CXCR4; the disease is lymphoma.